Bristol Myers Squibb Company has targeted cardiovascular disease as an important therapeutic area for expansion as it looks for new launches to diversify its commercial portfolio as its top sellers face generic and biosimilar competition. And, with recent milestones for its Factor XIa inhibitor milvexian and newly launched Camzyos (mavacamten), that part of the company’s growth strategy seems to be on track.
BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones
Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.